Literature DB >> 26976417

Can an Acidic Beverage Reduce Interactions Between Proton Pump Inhibitors and Erlotinib?

David Planchard1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26976417     DOI： 10.1200/JCO.2015.66.3344

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group.

Authors:  R Donald Harvey; Kathryn F Mileham; Vishal Bhatnagar; Jamie R Brewer; Atiqur Rahman; Cassadie Moravek; Andrew S Kennedy; Elizabeth A Ness; E Claire Dees; S Percy Ivy; Scot W Ebbinghaus; Caroline Schenkel; Thomas S Uldrick
Journal:  Clin Cancer Res       Date:  2021-02-09       Impact factor: 13.801

2.  Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.

Authors:  Andrea Gruber; Martin Czejka; Philipp Buchner; Marie Kitzmueller; Nairi Kirchbaumer Baroian; Christian Dittrich; Azra Sahmanovic Hrgovcic
Journal:  Cancer Chemother Pharmacol       Date:  2018-02-16       Impact factor: 3.333
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.